Cardiogen

Cardiogen is the cardiac entry in the Khavinson short peptide series, a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg. It follows the same product logic as the rest of the line: a bovine tissue extract came first, in this case the cardiac preparation Chelohart, the active peptide fraction was then characterised, and the defined four-residue synthetic peptide was released as the cleaner successor. Marketing positions it as a bioregulator for heart muscle, coronary microcirculation and the vascular system in ageing.

The proposed mechanism is the one that unifies the whole family. Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology argue that peptides of two to four residues can enter cells, reach the nucleus, and bind directly to specific DNA sequences and to histone proteins, thereby re-tuning transcription in a tissue-specific way. Biophysical support for at least the binding half of that claim exists: a 2013 study in Biochemistry (Moscow) examined interactions between these short peptides and histone-DNA complexes [3]. Whether such binding translates into meaningful, selective transcriptional control in an intact human heart is a much larger inferential jump, and it has not been demonstrated.

The experimental record specific to cardiac tissue is thin and old. The most directly relevant publication is a 2009 Advances in Gerontology paper reporting that cardiogen stimulated the development of myocardial tissue cultures taken from old rats, with explant growth in treated old-animal cultures approaching that seen in young-animal controls [1]. An earlier 2006 organotypic culture study from the same institute described tissue-specific effects across a panel of these synthetic bioregulators, with each peptide preferentially stimulating growth in the tissue from which its parent extract was derived [2]. The broader theoretical framework appears in Khavinson's 2002 review in Neuroendocrinology Letters [4].

Claims that circulate in the biohacking literature go considerably beyond that published core: reduced infarct size in ischaemia-reperfusion models, increased capillary density in ageing myocardium, elevated nitric oxide synthase activity, and reduced myocardial fibrosis in aged animals. Each of these is a standard endpoint in cardiovascular pharmacology and each would be genuinely interesting if reproduced. The difficulty is that these results are largely reported in Russian-language conference material and internal institute publications, are not consistently indexed in PubMed, and have not been reproduced by any independent group working in mainstream cardiovascular research. A reader cannot check them in the way one can check a trial published in a cardiology journal.

Human evidence is absent. There is no randomised controlled trial of Cardiogen in ischaemic heart disease, in heart failure, in post-infarct remodelling, or in any preventive cardiovascular setting. There is no registered study on ClinicalTrials.gov. There are no published human pharmacokinetics, which means the fundamental question of whether an injected tetrapeptide reaches cardiomyocyte nuclei in a person at any relevant concentration has never been answered. That combination places Cardiogen firmly at tier 4.

Dosing information in circulation comes from suppliers and user communities rather than from research: typically 2 to 4 mg per day, administered daily for two to four weeks, with the course repeated once or twice annually. The short cyclic pattern is standard across the Khavinson products and reflects the developers' theoretical position rather than any pharmacological dose-finding work.

The safety picture deserves more emphasis here than for most peptides on this site. Published reports describe only local injection-site reactions and occasional mild headache, and no systemic toxicity has been documented in animals. But a compound explicitly aimed at cardiac tissue, with no human safety data, no electrocardiographic monitoring in any published study, and no interaction data with anticoagulants, antiplatelet agents, beta blockers or antiarrhythmics, presents an obvious problem. The population most drawn to it, older adults with cardiovascular risk, is precisely the population in which an unstudied intervention is most consequential. The greatest realistic harm is not direct toxicity but substitution: someone using Cardiogen in place of, or in addition to, guideline-directed medical therapy without telling their cardiologist.

Sourcing is the other practical hazard. Cardiogen is not a licensed medicine in the United States, the United Kingdom or the European Union. Material obtained from grey-market vendors carries the usual risks of misidentification, underdosing, endotoxin contamination and non-sterile presentation, and no regulator is inspecting the manufacturing.

Our position: Cardiogen rests on a coherent theory, a small body of decades-old organotypic culture work from a single institute, and no human data. It should be regarded as an experimental compound. The step that would change that assessment is not another Russian review but an independent replication of the myocardial explant results, followed by a registered phase I study in humans.